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Abstract
Background: Strongyloidiasis, caused by an intestinal helminth Strongyloides stercoralis, is common throughout the tropics.
It remains an important health problem due to autoinfection, which may result in hyperinfection and disseminated infection
in immunosuppressed patients, especially patients receiving chemotherapy or corticosteroid treatment. Ivermectin and
albendazole are effective against strongyloidiasis. However, the efficacy and the most effective dosing regimen are to be
determined.
Methods: A prospective, randomized, open study was conducted in which a 7-day course of oral albendazole 800 mg daily
was compared with a single dose (200 microgram/kilogram body weight), or double doses, given 2 weeks apart, of
ivermectin in Thai patients with chronic strongyloidiasis. Patients were followed-up with 2 weeks after initiation of
treatment, then 1 month, 3 months, 6 months, 9 months, and 1 year after treatment. Combination of direct microscopic
examination of fecal smear, formol-ether concentration method, and modified Koga agar plate culture were used to detect
strongyloides larvae in two consecutive fecal samples in each follow-up visit. The primary endpoint was clearance of
strongyloides larvae from feces after treatment and at one year follow-up.
Results: Ninety patients were included in the analysis (30, 31 and 29 patients in albendazole, single dose, and double doses
ivermectin group, respectively). All except one patient in this study had at least one concomitant disease. Diabetes mellitus,
systemic lupus erythrematosus, nephrotic syndrome, hematologic malignancy, solid tumor and human immunodeficiency
virus infection were common concomitant diseases in these patients. The median (range) duration of follow-up were 19 (2–
76) weeks in albendazole group, 39 (2–74) weeks in single dose ivermectin group, and 26 (2–74) weeks in double doses
ivermectin group. Parasitological cure rate were 63.3%, 96.8% and 93.1% in albendazole, single dose oral ivermectin, and
double doses of oral ivermectin respectively (P=0.006) in modified intention to treat analysis. No serious adverse event
associated with treatment was found in any of the groups.
Conclusion/Significance: This study confirms that both a single, and a double dose of oral ivermectin taken two weeks
apart, is more effective than a 7-day course of high dose albendazole for patients with chronic infection due to S. stercoralis.
Double dose of ivermectin, taken two weeks apart, might be more effective than a single dose in patients with concomitant
illness.
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Introduction
Infection with the intestinal helminth Strongyloides stercoralis
remains a common problem throughout the tropics, including
Thailand [1,2]. It is estimated that 30 to 100 million people are
infected worldwide [1]. Most infected individuals are asymptomatic
or developed minimally symptomatic chronic infection through
autoinfection [3]. Potentially fatal disseminated infections, due to an
acceleration of the autoinfection cycle, are seen in immunocom-
promised patients, such as those with concurrent human T-
lymphotropic virus-1 (HTLV-1) infection, or those on corticosteroid
therapy [3,4]. Other recognized risk factors for disseminated
strongyloidiasis include malignancies especially lymphoma, organ
transplantation and diabetes mellitus [5,6]. Gastrointestinal symp-
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discomfort, nausea/vomiting and anorexia. The diagnosis of
strongyloidiasis should be suspected if there are clinical signs and
symptoms, or eosinophilia [7]. Definitive diagnosis of strongyloidi-
asis is usually made on the basis of detection of larvae in the stool
[8]. The combination of diagnostic approaches such as repeated
direct microscopic examination of fecal smear, fecal concentration
methods such as formol-ether concentration (FEC), and modified
Koga agar plate culture have been used to improve the likelihood of
detecting this parasite [7–11].
In the past, the treatment of choice for strongyloidiasis has been
thiabendazole, but this drug has unpleasant side effects and is no
longer available. Albendazole, another broad-spectrum antihel-
mintic agent, was previously shown to be effective against S.
stercoralis [12–15]. More recent reports suggest ivermectin, a
macrolide-like agent developed primarily for the treatment of
onchocerciasis, is as effective as thiabendazole [16] and superior to
albendazole against intestinal strongyloidiasis [17–21].
Although a single dose of ivermectin 200 microgram/kilogram
body weight (mg/kg) was shown to be effective in uncomplicated
chronic strongyloidiasis, repeated treatment at two or three week
intervals was thought to be necessary to eliminate larvae generated
by autoinfection [22].
A preparation of oral ivermectin licensed for human use has
recently become available in Thailand. However, albendazole
remains the most widely used antiparasitic drugs for the treatment
of this infection in this country. The purpose of the present study
was to assess the safety and efficacy of a single dose of ivermectin
(200 mg/kg), or two doses of ivermectin given 2 weeks apart, and a
7-day course of high dose albendazole for the treatment of chronic
strongyloidiasis in adult patients who were at high risk of
hyperinfection or disseminated infection.
Materials and Methods
Study design and ethics
This was a prospective open-label, randomised, controlled study
conducted between July 2008 and April 2010 at Siriraj Hospital,
Faculty of Medicine Siriraj Hospital, Mahidol University,
Bangkok, Thailand. The study was approved by the Ethical
Committee on Research Involving Human Subjects, Siriraj
Hospital, Faculty of Medicine, Mahidol University, Thailand.
All patients were informed about the purpose of the trial and gave
written informed consent before enrollment. The study enrollment
was stopped in December 2009 after 100 eligible patients had been
recruited.
Patients
Adult patients (.18 years) were recruited from Siriraj Hospital
if characteristic rhabditiform larvae of S. stercoralis were present on
fecal microscopy. Exclusion criteria included a history of allergic
reaction to either study medication, treatment within the month
prior to the study with any drug known to have anti-strongyloides
activity, pregnancy or lactation and any suggestion of disseminated
strongyloidiasis.
Treatment
Computer generated, simple, random allocation sequences were
prepared for 3 study groups by the investigator team. These were
sealed in an opaque envelope and numbered. The investigator
(YS) assigned study participants to their respective treatment group
after opening the sealed envelope. Once an eligible patient was
identified and informed consent was obtained, the patient was
randomly allocated to one of the following group (1:1:1 ratio):
1. Ivermectin-I group: a single oral dose of 200 mg/kg (Vermec-
tinH, Atlantic Laboratories Co, Ltd., Thailand).
2. Ivermectin-II group: two oral doses of 200 mg/kg of ivermectin
(VermectinH, Atlantic Laboratories Co, Ltd., Thailand) given 2
weeks apart.
3. Albendazole group: oral albendazole (AlbatelH, TO Chemical,
Thailand) 400 mg twice daily for 7 days.
Study Procedures
Baseline evaluation included history, detailed physical exami-
nation, and laboratory investigations such as complete blood count
(CBC), urinalysis, and biochemistry. Patients were requested to
collect two consecutive fecal samples at every hospital visit. The
coprodiagnosis for the detection of S. stercoralis larvae using direct
smear, formol-ether concentration method [9], and modified
Koga agar plate culture method [10] was performed for each
patient at the Infectious Diseases and Tropical Medicine
Laboratory, Division of Infectious Diseases and Tropical Medi-
cine, Faculty of Medicine Siriraj Hospital, Mahidol University,
Thailand.
Patients were required to make seven hospital visits to complete
the study: at baseline evaluation and initiation of treatment, at 2
weeks after initiation of treatment, then at 1 month, 3 months, 6
months, 9 months, and 1 year after treatment. Patients who
completed 1 year of follow-up were invited for further follow-up
visits every 3 months or at their convenience.
Outcome measures
Efficacy. The efficacy of treatment was analyzed on a
modified intention to treat, and a per-protocol basis. Modified
intention to treat analysis was based on the number of patients
who were randomized and received treatment. Per-protocol
analysis was based on the number of patients who completed
the treatment and were followed up as planned. Analyses of
adverse events were on the modified intention to treat basis.
Author Summary
Strongyloidiasis, caused by an intestinal helminth Strongy-
loides stercoralis, is common throughout the tropics. We
conducted a prospective, clinical study to compare the
efficacy and safety of a 7-day course of oral albendazole
with a single dose of oral ivermectin, or double doses,
given 2 weeks apart, of ivermectin in Thai patients who
developed this infection. Patients were regularly followed-
up after initiation of treatment, until one year after
treatment. Ninety patients were studied (30, 31 and 29
patients in albendazole, single dose, and double doses
ivermectin group, respectively). The average duration of
follow-up were 19 (range 2–76) weeks in albendazole
group, 39 ( range 2–74) weeks in single dose ivermectin
group, and 26 ( range 2–74) weeks in double doses
ivermectin group. Parasitological cure rate were 63.3%,
96.8% and 93.1% in albendazole, single dose oral
ivermectin, and double doses of oral ivermectin respec-
tively. No serious adverse event associated with treatment
was found in any of the groups. Therefore this study
confirms that both a single, and a double dose of oral
ivermectin taken two weeks apart, is more effective than a
7-day course of high dose albendazole for patients with
chronic infection due to S. stercoralis.
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‘‘Cure’’ was defined as clinical improvement (if symptomatic before
treatment) and the absence of rhabditiform larvae in the stool at
day14 of treatment and throughout the follow-up period. ‘‘Failure’’
w a sd e f i n e da st h ep r e s e n c eo fl a r v a et w ow e e k sa f t e ri n i t i a t i o no f
treatment or the reappearance of larvae during follow-up.
‘‘Adverse events’’ were defined as symptoms or signs that
developed after the study drug administration and had not been
reported prior to the administration of the first dose of the
antihelmintic.
Sample Size and Statistical Methods. Assuming the
therapeutic efficacy of albendazole to be 60% and of both
regimens of ivermectin treatment to be 90% [17–20,22], with
alpha error 0.5, and 80% power, it was calculated that 22 patients
would be needed in each study group. The lost to follow up rate
was assumed to be 20%. Therefore 27 patients would be needed in
each study group.
Demographic data, results of investigations, stool examination
at baseline and follow up visits were recorded in the database. All
statistical analyses were performed using SPSS, version 17.5.
Pearson chi square or Fisher’s exact tests were used to compare
rates and proportions, as appropriate. Mann-Whitney U tests were
used to analyze continuous variables that were not normally
distributed. Independent sample t- tests were used to compare
normally distributed variables, taking a probability of less than 5%
as the level of significance. Kaplan-Meier plot and Cox
proportional hazard model were constructed to identify indepen-
dent risk factors for treatment failure.
Results
One hundred and fifty one patients had detectable rhabditiform
larvae of S. stercoralis on fecal microscopy during the study period.
One hundred patients were enrolled (36, 32, and 32 patients in
albendazole, ivermectin-I, and ivermectin-II groups respectively).
Ten patients were excluded from analysis because they did not
receive or complete the study treatment (3 in albendazole group, 2
in ivermectin-II group), or they were lost to follow-up immediately
after treatment (3 in albendazole group, 1 each in ivermectin-I and
ivermectin-II respectively). Overall, 90 patients were eligible for
the modified intention to treat analysis. Detail of the total number
of enrollment, randomization, follow-up and inclusion in the final
analysis comparing among the three treatment groups is shown in
Figure 1.
The demographic data, concomitant diseases, baseline clinical
and laboratory investigations are shown in Table 1 and 2. All
except one patient had an associated medical problem, including
concurrent other parasitoses. These patients also had abnormal
serum aspartate aminotranferase (AST) and alanine aminotrans-
ferase (ALT) levels prior to entering the study due to their
underlying conditions.
The intensity of initial infection of the three study groups was
similar, i.e. S. stercoralis larvae were found from the direct fecal
examination in 24 (80%), 25 (80.6%), and 28 (96.6%) in
albendazole, Ivermectin-I, and ivermectin–II groups, respectively
(P=0.123). Larvae were also detected from modified Koga agar
plate culture in 22/26 (84.6%) patients in the albendazole group,
Figure 1. Total number of enrollment, randomization, follow-up, and inclusion in the final analysis comparing among three
treatment groups.
doi:10.1371/journal.pntd.0001044.g001
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(82.8%) patients in the ivermectin-II group, respectively
(P=0.976).
Diarrhea was detected in half of the patients and it was relieved
a f t e rt r e a t m e n ti nm o s tp a t i e n t s .A b n o r m a lb o w e lm o v e m e n ta t
second week of follow-up was reported in 4 patients in the
albendazole group, 2 patients in the ivermectin-I group, and 3
patients in the ivermectin-II group, respectively (P=0.641). S.
stercoralis larvae were detected in one patient in the ivermectin-I
group at thirdmonth of follow-up. In ivermectin-II group, S. stercoralis
larvae were detected at second week prior to the second dose of
ivermectin in two patients. No patients had reinfection/relapse after
the second dose of ivermectin treatment. In albendazole treated
patients, S. stercoralis larvae were detected at second week of follow-up
in 2 patients, at first month of follow-up in 2 patients, between 3–6
months of follow-up in 3 patients, and between 6–12 months of
follow-up in 4 patients. All of the relapses/ reinfections found during
follow-up were clinically inapparent.
Table 1. Demographic and baseline clinical features of the three study groups.
Characteristics
Albendazol
(N=30)
Ivermectin-I
(N=31)
Ivermectin –II
(N=29) P-value
Male: female 21:9 21:10 19:10 0.934
Median (range) age, yr 54 (23–81) 51 (29–77) 52 (25–78) 0.273
Median (range) weight, kg 59 (37–80) 57 (37–85) 59 (44–73) 0.75
Concomitant illnesses, n (%) 0.607
- None 1 0 0
- Diabetes mellitus 8 6 5
- NS/SLE 4 5 4
- AIDS/HIV infection 3 2 5
- Hematological malignancy 2 3 4
- Solid tumor 3 1 6
- Rheumatologic diseases 2 1 1
- Chronic kidney disease 3 2 2
- Alcohol drinker 3 1 1
- Others 6 12 4
Immunosuppressive drug, n (%) 10 (33.3) 11(35.5) 11 (37.9) 0.934
Concomitant parasitoses* 0.380
- Hookworm infection 2 1 0
- Opisthorchiasis 2 1 2
- Enterobious infection 0 1 0
- Entamoeba histolytica infection 0 1 0
- Isospora belli infection 0 0 1
*Diagnosis obtained by ova or cyst found from fecal examination.
doi:10.1371/journal.pntd.0001044.t001
Table 2. Comparison of symptoms related to chronic strongyloidiasis and baseline laboratory results.
Parameters
Albendazol
(N=30)
Ivermectin-I
(N=31)
Ivermectin –II
(N=29) P-value
Symptoms associated with strongyloidiasis, n (%)
- Diarrhea 14 (46.7) 11 (35.5) 16 (51.6) 0.609
- Abdominal pain 3 (10) 4 (12.9) 6 (20.7) 0.483
- Nausea/vomiting 4 (13.3) 4 (12.9) 6 (20.7) 0.650
Laboratory test, mean (SD)
- Hematocrit, % (35–45) 32.7 (7) 35.4 (6) 32 (8) 0.132
- Eosinophil count, 610
6/L (,500) 967(1,239) 1,203(2,714) 554(1,781) 0.366
- Total eosinophil .500/mL, n (%) 14 (46.7) 18 (58.1) 13 (44.8) 0.535
- AST, U/L (0–37) 45(43) 45(60) 38(34) 0.805
- ALT, U/L (0–40) 38(31) 42(38) 38(47) 0.924
- Creatinine, mg/dL (0.8–1.2) 1.2(0.5) 1.1(0.9) 0.8(0.8) 0.933
doi:10.1371/journal.pntd.0001044.t002
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(63.3%) albendazole treated patients, in 30 (96.8%) single-dose
ivermectin treated patients, and 27 (93.1%) two-dose ivermectin
treated patients (P=0.006) (Table 3). Cox regression analysis
showed that albendazole treated group had 14.7 times (95%CI
1.8–111.9), and 5.7 times (95%CI 1.3–25.7) higher risk for
reinfection/ relapse of strongyloidiasis than ivermectin-I and
ivermectin-II group, respectively. Kaplan- Meier Plot compares
the parasitological cure rate between these study groups is shown
in figure 2. No hyperinfection syndrome or disseminated infection
was found among these patients during the study period. S.
stercoralis larvae were detected after treatment using FEC in 8
patients, and by modified Koga agar plate culture only in 6 of
them. All patients with relapse/reinfection were retreated with two
doses of ivermectin in two weeks apart.
Overall albendazole and ivermectin were well tolerated. Transient
elevation of AST, and ALT levels was detected in one patient in
ivermectin-II group. The AST and ALT levels returned to normal 2
weeks after the second dose of ivermectin treatment. Severe nausea
and vomiting was reported in one patient in the albendazole group.
Fifteen patients died after enrollment (5 patients in each
treatment group). Causes of death were not related to the study
drugs, and were considered to be due to an underlying disease or
its complications (solid tumor in 5, hematologic malignancies in 3,
diabetes mellitus, or systemic lupus erythrematosus (SLE), or
hypertension with complications such as myocardial infarction or
sepsis in 7 patients). The median duration from enrollment to
death was 2 weeks (range 2–14 weeks) in the albendazole group, 5
weeks (range 2–38 weeks) in the ivermectin-I group, and 2 weeks
(range 1–27 weeks) in the ivermectin-II group, respectively.
Discussion
Strongyloidiasis remains a significant health problem in many
developing countries, mainly due to the potential for lethal
Table 3. Outcome of treatment among the three study groups.
Parameters
Albendazol
(N=30)
Ivermectin-I
(N=31)
Ivermectin-II
(N=29) P-value
Duration of follow up
- Median (range), weeks 19(2–76) 39(2–74) 26 (2–74) 0.248
Outcome: Parasitological responses 0.006
- Elimination, n (%) 19 (63.3) 30 (96.8) 27 (93.1)
- Failure 11 (36.7) 1 (3.2) 2 (6.9)
- Persistence at 2 week 2 0 2
- Relapse /reinfection 9 1 0
doi:10.1371/journal.pntd.0001044.t003
Figure 2. Kaplan-Meier Plot comparing the parasitological cure among the albendazole, ivermectin-I, and ivermectin-II treatment
groups over one year follow-up period.
doi:10.1371/journal.pntd.0001044.g002
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with strongyloidiasis found in this study included diarrhea,
abdominal discomfort, nausea/vomiting and anorexia. Chronic
infection with S. stercoralis was clinically inapparent in half of the
patients at enrollment, and in all of relapses/ reinfections found
during follow up. Peripheral eosinophilia (.500 eosinophils/mL.)
was detected in half of the patients at enrollment. S. stercoralis
larvae were detected after treatment using FEC in 8 patients, and
by modified Koga agar plate culture in 6 patients. This
information confirmed that fecal examination, including culture
and/or serology, every 3–6 months of follow-up should be
recommended for early detection and treatment of latent infection
to prevent hyperinfection or disseminated disease in these patients
[3,5].
Results of this study corroborate the results from previous
randomised controlled studies on the higher efficacy of ivermectin
compared to various dosage regimens of albendazole for treating
chronic strongyloidiasis [17–21]. A summary of results from these
previous controlled trials of ivermectin treatment for chronic
strongyloidiasis is shown in Table 4. Although these studies were
conducted in different geographical areas and population groups,
i.e. in children and adults, they were considered to be within a
community-based setting, such as schools or primary care clinic.
The duration of follow-up varied from 3 weeks to 12 months. The
present study was conducted in a tertiary hospital. The majority of
patients had known risk factors for disseminated strongyloidiasis,
and approximately one-third of them received corticosteroid or
chemotherapy. Results of this study confirmed that ivermectin was
also effective in this population who were at high risk of severe
infection.
Albendazole remains an option of treatment for chronic
strongyloidiasis in many countries in South East Asia, where oral
ivermectin is not widely available. Cure rates of a regimen
consisting of albendazole 400 mg daily for three to five days varied
from 38–87% in those without underlying diseases [14,17–20]. In
this study, the cure rate was found to be 63% when a 7-day course
of high dose albendazole was used. The efficacy of albendazole
varied widely even when the same dose and duration of treatment
was used. Differences in duration of follow-up examinations could
be one explanation, and re-infection from the environment may
also be a factor when the efficacy is monitored for an extended
period in endemic areas. The study which reported the highest
cure rate (87%) was conducted in Okinawa, Japan [19], where the
chance of re-infection from the environment was less likely to
occur compared to other studies conducted in endemic areas
[17,18,20,21].
Two patients in the ivermectin-II group had detectable S.
stercoralis larvae in the second week prior to the second dose of
ivermectin treatment. One patient in ivermectin-I group also had
detectable S. stercoralis larvae 3 months after treatment. This
observation supports the recommendation that repeated doses of
ivermectin should be the preferred treatment in patients with
chronic strongyloidiasis who have an underlying or concomitant
illness [22].
The limitation of this study was the high loss to follow-up rates
over time. High mortality associated with the concomitant
illnesses was an unavoidable cause of concern in this study.
The median duration of follow up was 19 weeks in albendazole
group, 39 weeks in ivermectin-I, and 26 weeks in ivermectin-II
group. The non-significant shorter duration of follow up found in
albendazole treatment group was due to the significant higher
rate of treatment failure compared to ivermectin. However, the
study still had sufficient power to detect a difference between
albendazole and ivermectin treatments. This study, however, was
too small to detect any but the most severe and common side-
effects of both albendazole and ivermectin. Only one of
albendazole treated patients and one treated with ivermectin
had transient changes in transaminases, a well-recognized and
reversible adverse event.
In conclusion, this clinical study confirms that both a single and
a double dose of oral ivermectin taken at a two-week interval is
more effective than a 7-day course of high dose of albendazole for
patients with chronic infection due to S. stercoralis.
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Table 4. Summary of published controlled trials of oral ivermectin treatment for chronic strongyloidiasis.
Comparative Drug, Dosage Regimen
Duration
of follow-up N
Cure,
N( % )
Author,
year, [Ref]
1. Albendazole 400 mg/d - 3days
2. Ivermectin 150–200 mg/kg, single dose
30 days 24
29
9( 3 8 )
24 (83)
Datry A,
1994 [17]
1. Thiabendazole 50 mg/kg/day - 3 days
2. Ivermectin 200 mg/kg, single dose
3. Ivermectin 200 mg/kg, - 2 days
7 days, then
1, 3, 6
months
19
16
18
18(94.7)
16(100)
18(100)
Gann PH,
1994 [16]
1. Albendazole 400 mg/d -3 days
2. Ivermectin 200 mg/kg, single dose
3 weeks 149
152
67(45)
126(82.9)
Marti H,
1996 [18]
1. Pyrvinium pamoate 5 mg/kg/d -3 days
2. Albendazole 400 mg/d - 3days
3. Ivermectin 6 mg 2 doses- 2 weeks apart
2 weeks,
then 6, 12
months
60
84
67
14 (23.3)
65 (77.4)
65 (97)
Toma H,
2000 [19]
1. Albendazole 400 mg/d - 5 days
2. Ivermectin 150–200 mg/kg, single dose
30 days 33
78
26(78.8)
77(98.7)
Nontasut P,
2005 [20]
doi:10.1371/journal.pntd.0001044.t004
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